Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
SYDNEY, Australia, Aug. 20, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that Grant Chamberlain will join the Board as a Non-Executive Director with immediate effect.
Mr Chamberlain brings extensive corporate finance and capital markets experience to Prima’s Board. Formerly Head of Mergers & Acquisitions and Financial Sponsors for Bank of America Merrill Lynch in Australia, Mr Chamberlain has more than twenty years experience in investment banking including former positions at Deutsche Bank and Nomura. He has advised major Australian and international companies on strategy, mergers and acquisitions and capital markets transactions.
Prima BioMed Chair Lucy Turnbull said: “We are delighted to welcome Grant to the Prima Board. His Australian and international markets experience will be a valuable asset as we progress our clinical development programs and consolidate our global leadership in LAG-3.”
Grant Chamberlain, on his appointment said: “I am honoured to join Prima’s Board. I have tremendous respect for Lucy and her fellow Directors and I’m excited about the potential of Prima’s LAG-3 technology. I look forward to contributing to Prima’s future success.”
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
